Novel biomarkers for the early prediction of pediatric cystic echinococcosis post-surgical outcomes - 05/01/22
Highlights |
• | We identified 59 proteins specific to relapsed patients using comparative proteomics. |
• | Cytoplasmic malate dehydrogenase and citrate synthase are promising early biomarkers. |
• | ELISA using cytoplasmic malate dehydrogenase is the best tool to predict CE outcomes. |
Summary |
Objective |
This study aims to search for reliable serological biomarkers allowing the early prediction of cystic echinococcosis (CE) post-operative outcomes.
Methods |
We applied immunoprecipitation (IP) of Echinococcus granulosus protoscolex antigens with pediatric CE patients' plasma collected at 1-month and 1-year post-surgery, followed by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS). We compared IP proteomic content from relapsed patients within the first-year post-surgery (RCE) to cases with no relapses until 3 post-operative years (NRCE). Selected proteins were recombinantly synthesized and assessed for their prognostic performance by Enzyme-linked immunosorbent assay (ELISA).
Results |
A total of 305 immunoreactive parasitic proteins were identified, 59 of which were significantly more abundant in RCE than NRCE for both time-points. Four proteins showed the most promising characteristics for predicting CE outcomes: cytoplasmic malate dehydrogenase (Eg-cMDH), citrate synthase (Eg-CS), annexin A6 and severin. ELISA-IgG against the four markers were significantly lower at 1-year post-surgery than 1-month in NRCE, in contrast to RCE that displayed either stable or higher levels. The Eg-cMDH and Eg-CS showed the best prognostic performance, with respective probabilities of being “relapse-free” of 83% and 81%, if a decrease of IgG levels occurred between 1-month and 1-year post-surgery.
Conclusion |
The Eg-cMDH and Eg-CS are promising biomarkers to predict early CE post-surgical outcomes.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Keywords : Predictive biomarkers, Serological follow-up, Cystic echinococcosis, Post-surgical outcomes, Pediatric patients, Proteomics, ELISA
Plan
Vol 84 - N° 1
P. 87-93 - janvier 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?